Lilly (LLY) obesity pill reduces cardiovascular risks in trial
Published on · Source: cnbc.com
AI Summary
Summarized by AI from the source belowEli Lilly (LLY) announced that its Foundayo obesity pill met its trial goals by reducing the risk of major cardiovascular events by 16% in over 2,700 adults with type 2 diabetes. Compared to insulin glargine, patients taking Foundayo experienced a 57% lower risk of death from any cause. Additionally, those on Foundayo had greater reductions in blood sugar and weight, unlike patients on insulin glargine who gained weight. Eli Lilly plans to seek U.S. approval for Foundayo for type 2 diabetes by the end of Q2.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Eli Lilly and Company (LLY)
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier LLY news
- Eli Lilly (LLY) market share drops to 56% in India as generics flood
- Senator Angus King Jr. Sells $1,000 to $15,000 in Autodesk (ADSK)
- Eli Lilly (LLY) Receives FDA Approval for Weight Loss Pill, Acquires Centessa
- Eli Lilly (LLY) Acquires Centessa for $7.8 Billion
- Eli Lilly (LLY) Stock Rating Reiterated After Obesity Drug Approval
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
